亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Abstract 14714: Long-Term Neurocognitive Safety of LDL-C Lowering With Evolocumab: Open-Label Extension Data From FOURIER

医学 Evolocumab公司 安慰剂 中止 情景记忆 认知功能衰退 不利影响 随机对照试验 内科学 认知 精神科 痴呆 替代医学 疾病 载脂蛋白A1 病理 胆固醇 载脂蛋白B
作者
André Zimerman,Michelle L. O’Donoghue,Xinhui Ran,KyungAh Im,Brian F Ott,François Mach,Kenton H. Zavitz,Christopher E. Kurtz,Maria Laura Monsalvo,Bei Wang,Dan Atar,Anthony Keech,Marc S. Sabatine,Robert P. Giugliano
出处
期刊:Circulation [Ovid Technologies (Wolters Kluwer)]
卷期号:148 (Suppl_1)
标识
DOI:10.1161/circ.148.suppl_1.14714
摘要

Background: Concerns have been raised about low LDL-C levels and possible adverse effects on cognition. PCSK9 inhibitors markedly lower LDL-C, yet EBBINGHAUS, a prespecified substudy within the FOURIER trial, did not show adverse cognitive changes with evolocumab over 19 months median follow-up. Purpose: To investigate the long-term effects of evolocumab on cognitive function. Methods: EBBINGHAUS was a substudy of cognitive function using the Cambridge Neuropsychological Test Automated Battery (CANTAB) within the FOURIER randomized trial of evolocumab vs placebo in patients with established ASCVD. Patients in North America and Europe who completed EBBINGHAUS on study drug were eligible for an open-label extension (OLE) study with evolocumab. The primary endpoint was change in spatial working memory strategy index of executive function score (SWMI) from baseline over time. Secondary endpoints were measures of working memory, episodic memory, and psychomotor speed. A paired t-test was used to compare baseline vs post-baseline scores during OLE. Results: Of 1204 patients from EBBINGHAUS, 306 entered the OLE and were treated with evolocumab for a median of 5.1 years. Median achieved LDL-C was 34 mg/dL (IQR 21-50). No significant change in SWMI occurred during the OLE period overall [mean (±SD) change -0.1±2.7, p=0.73] or when stratified by original randomized allocation ( Figure 1A ). For secondary outcomes, one showed no change during the OLE period, two showed small changes (10-15% of SD), but these were directionally inconsistent (one higher, one lower). In 152 patients originally randomized to evolocumab, there was no significant change in SWMI from randomization through long-term follow-up over a median of 6.7 and a maximum of 7.2 years (mean change 0.1±2.6, p=0.66) ( Figure 1B ). Conclusion: Evolocumab did not lead to any apparent long-term decline in cognitive function through follow-up extending up to 7.2 years.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
jiemo_111完成签到,获得积分10
2秒前
liujingyi发布了新的文献求助10
4秒前
酷拉皮卡发布了新的文献求助10
8秒前
小天发布了新的文献求助10
8秒前
深情安青应助李雅欣采纳,获得10
9秒前
悦耳冬萱完成签到 ,获得积分10
9秒前
薛建伟完成签到,获得积分10
14秒前
Xu完成签到 ,获得积分10
17秒前
allen完成签到,获得积分10
26秒前
FashionBoy应助薛建伟采纳,获得10
31秒前
linelolo完成签到,获得积分10
35秒前
djbj2022发布了新的文献求助100
38秒前
CipherSage应助zzy采纳,获得10
38秒前
linelolo发布了新的文献求助10
39秒前
46秒前
q1nzang完成签到 ,获得积分10
46秒前
善良的灵羊完成签到 ,获得积分10
46秒前
薛建伟发布了新的文献求助10
50秒前
52秒前
zzzzzz完成签到,获得积分10
52秒前
Jimmy完成签到,获得积分10
53秒前
tongluobing完成签到,获得积分10
56秒前
浮游应助科研通管家采纳,获得10
58秒前
bkagyin应助科研通管家采纳,获得10
59秒前
仓颉完成签到,获得积分10
59秒前
科研通AI2S应助科研通管家采纳,获得10
59秒前
李雅欣发布了新的文献求助10
59秒前
浮游应助科研通管家采纳,获得10
59秒前
wayne完成签到 ,获得积分10
1分钟前
Akim应助仓颉采纳,获得10
1分钟前
华仔应助madoudou采纳,获得10
1分钟前
eleven完成签到,获得积分10
1分钟前
1分钟前
1分钟前
emo呼噜噜发布了新的文献求助20
1分钟前
1分钟前
小天发布了新的文献求助30
1分钟前
大胆妖精完成签到 ,获得积分10
1分钟前
madoudou发布了新的文献求助10
1分钟前
完美凝竹完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Treatise on Geochemistry (Third edition) 1600
Clinical Microbiology Procedures Handbook, Multi-Volume, 5th Edition 1000
List of 1,091 Public Pension Profiles by Region 981
医养结合概论 500
On the application of advanced modeling tools to the SLB analysis in NuScale. Part I: TRACE/PARCS, TRACE/PANTHER and ATHLET/DYN3D 500
L-Arginine Encapsulated Mesoporous MCM-41 Nanoparticles: A Study on In Vitro Release as Well as Kinetics 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5458817
求助须知:如何正确求助?哪些是违规求助? 4564825
关于积分的说明 14296985
捐赠科研通 4489857
什么是DOI,文献DOI怎么找? 2459372
邀请新用户注册赠送积分活动 1449054
关于科研通互助平台的介绍 1424535